Migraine Therapy

References

• Cady R K, Everett K L. Introduction. Treating the headache patient, R K Cady, A W Fox. Marcel Dekker Inc., New York 1994; 1–14
   Google Scholar
• Lipton R B, Stewart W F, Diamond S, Diamond M L, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646–657
   PubMed Web of Science ®Google Scholar
• Stewart W F, Lipton R B, Celentano D D, Reed M L. Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemo-graphic factors. JAMA 1992; 267: 64–69
   PubMed Web of Science ®Google Scholar
• Stang P E, Yanagihara P A, Swanson J W. Incidence of migraine headache: A population-based study in Olmsted County, Minnesota. Neurology 1992; 42: 1657–1662
   PubMed Web of Science ®Google Scholar
• Rasmussen B K. Epidemiology of headache. Cephalalgia 1995; 15: 45–68
   PubMed Web of Science ®Google Scholar
• Fox A W, Davis R L. Migraine chronobiology. Headache 1998; 38: 436–441
   PubMed Web of Science ®Google Scholar
• Clouse J C, Osterhaus J T. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659–664
   PubMed Web of Science ®Google Scholar
• Stang P E, Osterhaus J T. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache 1993; 33: 29–35
   PubMed Web of Science ®Google Scholar
• Osterhaus J T, Gutterman D L, Plachetka J R. Healthcare resource and lost labour costs of migraine headache in the United States. Pharmacoeconomics 1992; 2: 67–76
   PubMedGoogle Scholar
• Wall M, Silberstein S D, Aiken R D. Headache associated with abnormalities in intracranial structure or function: High cerebrospinal fluid pressure headache and brain tumor. Wolff's headache and other head pain, 7th edition, S D Silberstein, R B Lipton, D J Dalessio. Oxford University Press, OxfordUK 2001; 393–416
   Google Scholar
• The anatomy of the human body by Henry Gray FRS, 30th edition, C D Clemente. Lea & Febiger, Philadelphia 1985; 1125: 1158–1169
   Google Scholar
• Graham J R, Wolff H G. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psych 1938; 39: 737–763
   Google Scholar
• Heyck H. Pathogenesis of migraine. Res Clin Studies Headache 1969; 2: 1–28
   Google Scholar
• Saito K, Markowitz S, Moskowitz M A. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches. Ann Neurol 1988; 24: 732–737
   PubMed Web of Science ®Google Scholar
• Lorenz K. Ergot on cereal grains. CRC Crit Rev Food Sci Nutr 1979; 11: 311–354
   PubMedGoogle Scholar
• Tudzynski P, Correia T, Keller U. Biotechnology and genetics of ergot alkaloids. Appl Microbiol Biotechnol 2001; 57: 593–605
   PubMed Web of Science ®Google Scholar
• Diekman M A, Green M L. Mycotoxins and reproduction in domestic livestock. J Anim Sci 1992; 70: 1615–1627
   PubMed Web of Science ®Google Scholar
• Vogt Engeland I, Andresen O, Ropstad E, Kindahl H, Waldeland H, Daskin A, Olav Eik L. Effect of fungal alkaloids on the development of pregnancy and endocrine foetal-placental function in goat. Anim Reprod Sci 1998; 52: 289–302
   PubMed Web of Science ®Google Scholar
• Bermejo Sanchez E, Rodriguez-Pinella E, Martinez-Frias M L. Use of ergot derivatives during gestation: the ECEMC experience. Reprod Toxicol 1993; 7: 155
   Google Scholar
• Baskett T F. A flux of the reds: Evolution of active management of the third stage of labour. J Roy Soc Med 2000; 93: 489–493
   PubMed Web of Science ®Google Scholar
• Thoms H. John Stearns and pulvis parturiens. Am J Obstet Gynecol 1931; 22: 418–423
   Google Scholar
• Degroot A NJA, Van Dongen P WJ, Van Roosmalen J. Ergotamine-induced fetal distress: Review of side-effects of ergot alkaloids during pregnancy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 73–77
   PubMed Web of Science ®Google Scholar
• Brucker M C. Management of the third stage of labor: An evidence-based approach. J Midwif Womens Health 2001; 46: 381–392
   PubMed Web of Science ®Google Scholar
• Raymond G V. Teratogen update: Ergot and ergotamine. Teratology 1995; 51: 344–347
   PubMedGoogle Scholar
• Zavaleta E G, Fernandez B B, Grove M K, Kaye M D. St. Anthony's fire (ergot-induced leg ischemia)-a case report and review of the literature. Angiology 2001; 52: 349–356
   PubMed Web of Science ®Google Scholar
• Christopoulos S, Szilagyi A, Kahn S R. St. Anthony's fire. Lancet 2001; 358: 1694
   PubMed Web of Science ®Google Scholar
• Spanos N P. Ergotism and the Salem witch panic: A critical analysis and an alternative conceptualization. J Hist Behav Sci 1983; 19: 358–369
   PubMed Web of Science ®Google Scholar
• Peroutka S J. Drugs effective in the treatment of migraine. The pharmacological basis of therapeutics, Ninth edition, J G Hardman, L E Limbird, P Molinoff, R W Ruddon, A G Gilman. McGraw-Hill, New York 1995; 491–493, 495, 496
   Google Scholar
• Dale H H. Onsome physiological actions of ergot. J Physiol 1906; 34: 163–206
   PubMedGoogle Scholar
• Horton B T, Peters G A, Blumenthal L S. A new product in the treatment of migraine: A preliminary report. Proc Staff Mtg Mayo Clin 1945; 20: 241–248
   Web of Science ®Google Scholar
• Chu D, Owen D AA, Sturmer E. Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad Med J 1976; 52(Suppl 1)32–37
   Google Scholar
• Peroutka S J, Havlik S, Oksenburg D. Antimigraine drug interactions with cloned human 5-HT1 receptor subtypes. Headache 1993; 33: 347–350
   PubMed Web of Science ®Google Scholar
• McCarthy B G, Peroutka S J. Comparative neuropharmacology of dihydro-ergotamine and sumatriptan (GR43175). Headache 1989; 29: 420–422
   PubMed Web of Science ®Google Scholar
• Schoeffter P, Hoyer D. How selective is GR43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C, and 5-HT1D receptors. Naunyn-Schmiedeburg's Arch Pharmacol 1989; 340: 135–138
   PubMed Web of Science ®Google Scholar
• Humphrey P PA, Feniuk W, Perren M J, Connor H E, Oxford A W. The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia 1989; 9(Suppl 2)23–33
   PubMedGoogle Scholar
• Humphrey P PA, Feniuk W, Marriott A S, Taner R JN, Jackson M R, Tucker M L. Preclinical studies on the anti-migraine drug sumatriptan. Eur Neurol 1991; 29: 91–94
   Google Scholar
• Peroutka S J. 5-hydroxytryptamine receptor sub-types and the pharmacology of migraine. Neurology 1993; 43(Suppl 3)S34–S38
   PubMedGoogle Scholar
• Cady R K, Wendt J K, Kirchner J R, Sargent J D, Rothrock J F, Skaggs H. Treatment of acute migraine with sumatriptan. JAMA 1991; 265: 2831–2835
   PubMed Web of Science ®Google Scholar
• Simmons V E, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319–328
   Google Scholar
• O'Quinn S, Davis R L, Gutterman D L, Pait G D, Fox A W. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999; 19: 223–231
   PubMed Web of Science ®Google Scholar
• Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, Koren G. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51: 581–588
   PubMed Web of Science ®Google Scholar
• O'Quinn S, Ephross S A, Williams V, Davis R L, Gutterman D L, Fox A W. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: A prospective study. Arch Gynecol Obstet 1999; 263: 7–12
   PubMed Web of Science ®Google Scholar
• Fox A W, Chambers C D, Anderson P O, Diamond M L, Spierings E LH. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8–15
   PubMed Web of Science ®Google Scholar
• Fox A W. Comparative tolerability of oral 5HT1B/1D agonists. Headache 2000; 40: 521–527
   PubMed Web of Science ®Google Scholar
• Saxena P R, DeVlaam S G. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine. Studies in experimental animal model for migraine. Headache 1974; 13: 142–146
   PubMed Web of Science ®Google Scholar
• Peroutka S J, Snyder S H. Multiple serotonin receptors: Differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Mol Pharmacol 1979; 687–689
   PubMed Web of Science ®Google Scholar
• Lance J W, Fine R D, Curran D A. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Austral 1963; 1: 814–818
   Web of Science ®Google Scholar
• Silberstein S D. Methysergide. Cephalalgia 1998; 18: 421–435
   PubMed Web of Science ®Google Scholar
• Khan M A, Herzog C A, St.Peter J V, Hartley G G, Madlon-Kay R, Dick C D, Asinger R W, Vessey J T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Eng J Med 1998; 339: 713–718
   PubMed Web of Science ®Google Scholar
• Jick H, Vasilakis C, Weinrauch L A, Meier C R, Jick S S, Derby L E. A population-based study of appetite-suppressant drugs and the risk of cardiac valve regurgitation. N Eng J Med 1998; 339: 719–724
   PubMed Web of Science ®Google Scholar
• Weissman N J, Tighe J F, Gottdiener J S, Gwynne J T, for The Sustained-Release Dexfenfluramine Study Group
   Google Scholar
• Weissman N J, Tighe J F, Gottdiener J S, Gwynne J T, for The Sustained-Release Dexfenfluramine Study Group. An assessment of heart valve abnormalities on obese
   Google Scholar
• Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med 1987; 82: 4–16
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference, 54th edition. Medical Economics Co., Montvale, NJ 2000; 433: 1753–3251
   Google Scholar
• McChesney J D. Development of herbal medicinals: A pharmaceutical perspective. J Herbal Pharmacother 2001; 1: 51–79, (The quote is taken from p. 66.)
   Google Scholar
• Silberstein S D, Saper J R, Freitag F. Migraine diagnosis and treatment. Wolff's headache and other head pain, S D Silberstein, R B Lipton, D J Dalessio. Oxford University Press, Oxford 2001; 176–199
   Google Scholar
• Physician's Desk Reference, 54th edition. Medical Economics Company, Montvale, New Jersey 2001; 433–435, 1753, 3251
   Google Scholar
• Diener H C. Sumatriptan in the treatment of cluster headache. Cephalalgia 2001; 21(suppl 1)16–17
   PubMedGoogle Scholar
• Murphy J J, Heptinstall S, Mitchell J R. Randomised, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2: 189–192
   PubMed Web of Science ®Google Scholar
• Johnson E S, Kadam N P, Hylands D M, Hylands P J. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res) 1985; 291: 569–573
   PubMed Web of Science ®Google Scholar
• Grossmann M, Schmidramsl H. An extract of Petasites hybridus, is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38: 430–435
   PubMed Web of Science ®Google Scholar
• Anderson D, Jenkinson P C, Dewdney R S, Blowers S D, Johnson E S, Kadan N P. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: A comparison of chronic feverfew users and matched non-users. Hum Toxicol 1988; 7: 145–152
   PubMedGoogle Scholar
• Barsby R W, Salan U, Knight D W, Hoult J R. Feverfew and vascular smooth muscle: Extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993; 59: 20–25
   PubMed Web of Science ®Google Scholar
• Fox A W, de Sousa E AJ. “Herbal” remedies and patient protection. Headache 2001; 41: 323–324
   PubMed Web of Science ®Google Scholar
• Koch V, Danesch U. Response to Fox and de Sousa. Headache 2001; 41: 325–326
   Google Scholar
• Ernst E, Pittler M H. The efficacy and safety of feverfew (Tanacetum parthen-ium): An update of a systematic review. Public Health Nutr 2000; 3: 509–514
   PubMedGoogle Scholar
• Barnes J, Mills S Y, Abbot N C, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies. Br J Clin Pharmacol. 1998; 45: 496–500
   PubMed Web of Science ®Google Scholar
• Huxtable R J. The myth of beneficient nature: The risks of herbal preparations. Ann Int Med 1992; 117: 165–166
   PubMed Web of Science ®Google Scholar
• Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170–178
   PubMed Web of Science ®Google Scholar
• Cupp M J. Herbal remedies: Adverse effects and drug interactions. Am Fam Phys 1999; 59: 1239–1245
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Chan T YK, Chan J CN, Critchley J AJH, But P PH. Toxicity of complementary therapies: An Eastern perspective. J Clin Pharmacol 2000; 40: 451–456
   PubMed Web of Science ®Google Scholar
• Nortier J L, Muniz Martinez M C, Schmeiser H H, Arlt V M, Bielier C A, Petein M, Depierreux M F, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem J L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia Fangchi). New Eng J Med 2000; 342: 1686–1692
   PubMed Web of Science ®Google Scholar
• Putnam G P, O'Quinn S, Bolden-Watson C P, Davis R L, Gutterman D L, Fox A W. Migraine polypharmacy and the tolerability of sumatriptan: A large-scale, prospective study. Cephalalgia 1999; 19: 668–675
   PubMed Web of Science ®Google Scholar
• Andersen J S. Clinical trial designs-made to order. J Biopharm Stat 1996; 6: 515–522
   PubMedGoogle Scholar
• United States Code of Federal Regulations. Title 21, 10: 115, 312: 145, and references therefrom
   Google Scholar
• Kroll D J. Concerns and needs for research in herbal supplement pharmacotherapy and safety. J Herbal Pharmacother 2001; 1(2)3–23
   Google Scholar